Its sales revenues were at RON149.78 million in the first six months, up 5.6% from RON141.85 million in January-June 2013.
Antibiotice also registered a 5.21% sales growth on the local market, at RON103.8 million.
On the Romanian market, Antibiotice ranks 12th, with a 2.58% share in the second quarter.
The company plans to build new production capacities needed for the development of its medicines portfolio. Investments are estimated to amount to EUR40 million in the next six years.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53.02% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10.32% stake. (EUR1=RON4.4415)
Antibiotice shares closed flat at RON0.573 in Bucharest Wednesday. (EUR1=RON4.4372)